BioSpace News Archive

Medtronic plc announced that Sean Salmon, Executive Vice President and President, Diabetes Operating Unit has been named Executive Vice President and President, Cardiovascular Portfolio effective January 1.

Safe Medical Design, a company focused on reducing complications caused by the use of urethral catheters, recently published data demonstrating the effectiveness of their Signal Catheter® in reducing intraurethral pressure and limiting balloon diameter that leads to urethral trauma when the catheter is inadvertently inflated in the urethra during placement.

Nortech Systems Incorporated (Nasdaq: NSYS), a leading provider of engineering and manufacturing solutions for complex electromedical and electromechanical products serving the medical, aerospace & defense and industrial markets, announced today Phil Smith and Dan Sachs were recently appointed to the company’s board of directors. This press release features multimedia.

An important part of the brain’s immune system, cells called microglia constantly extend and retract “branches” from their cell body to survey their environment.

TG Therapeutics, Inc., a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, announced the pricing of an underwritten public offering of 6,320,000 shares of common stock at a public offering price of $43.50 per share.

During height of coronavirus pandemic, nine rogue drug companies announce they are refusing to provide certain drugs at the legally required ‘340B price’ as required by section 340B of the U.S. Health Services Act

Quantum Health, the leading consumer healthcare navigation and care coordination company, is now integrating vaccine care planning into its core service offering

Zynx Health® today announced that it has published a new, publicly available review of vaccine administration guidelines specific to COVID-19 vaccines, including Pfizer/BioNTech BNT162b2, the COVID-19 vaccine co-developed by Pfizer and BioNTech, following its emergency use approval by the U.S. Food and Drug Administration (FDA).

TetraGenetics , a biopharmaceutical company developing novel antibody therapeutics for ion-channel mediated disorders, announced today that they will be presenting news of the discovery of functional antibodies against Nav1.8 at the Antibody Engineering & Therapeutics Virtual Conference taking place Dec 14 th – 16 th . The success of TetraGenetics is based on its strategy for identifying function-modulating antibodies

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a corporate update. The webcast will begin at 9.00am AEDT, Tuesday, December 15; 5.00pm EST, Monday, December 14, 2020. It can be accessed via https://webcast.boardroom.media/mesoblast-limited/20201214/NaN5fd6e483de11ae0019f60917 The archived webcast will be available on the Investor page of the